

Study Title: Load Modification Versus Standard Exercise to Inform Treatment for Individuals With Greater Trochanteric Pain Syndrome.

NCT: NCT03571971

Date: January 31, 2022

1
2 **The Ohio State University Combined Consent to Participate in**
3 **Research and HIPAA Research Authorization**
4
5

Study Title: Load modification versus standard exercise to inform treatment for individuals with greater trochanteric pain syndrome

Principal Investigator: Stephanie Di Stasi Roewer

Sponsor: Foundation for Physical Therapy

6
7 • **This is a consent form for research participation.** It contains important information
8 about this study and what to expect if you decide to participate. Please consider the
9 information carefully. Feel free to discuss the study with your friends and family and to
10 ask questions before making your decision whether or not to participate.
11
12 • **Your participation is voluntary.** You may refuse to participate in this study. If you
13 decide to take part in the study, you may leave the study at any time. No matter what
14 decision you make, there will be no penalty to you and you will not lose any of your
15 usual benefits. Your decision will not affect your future relationship with The Ohio State
16 University. If you are a student or employee at Ohio State, your decision will not affect
17 your grades or employment status.
18
19 • **You may or may not benefit as a result of participating in this study.** Also, as
20 explained below, your participation may result in unintended or harmful effects for you
21 that may be minor or may be serious depending on the nature of the research.
22
23 • **You will be provided with any new information that develops during the study that
24 may affect your decision whether or not to continue to participate.** If you decide to
25 participate, you will be asked to sign this form and will receive a copy of the form. You
26 are being asked to consider participating in this study for the reasons explained below.


27 1. **Why is this study being done?**

28 The purpose of this study is to compare the effects of two different physical therapy
29 programs on pain and function in individuals diagnosed with greater trochanteric pain
30 syndrome (GTPS). You are being asked to participate in this study because your physician
31 has confirmed that you have a diagnosis of GTPS (also known as lateral hip pain). Physical
32 therapy is a common treatment option, but has mixed results. We are trying to understand
33 what the most effective program is for optimizing function and reducing pain for the
34 majority of individuals with GTPS.

35 2. **How many people will take part in this study?**

Up to 64 subjects will participate in this study.

36 3. What will happen if I take part in this study?



37 The figure to the left provides details of the
38 testing and treatment involved in this study. If
39 you choose to participate, you will be randomly
40 assigned one of two physical therapy treatment
41 groups, standard exercise education or load
42 modification education. You have an equal
43 chance of being assigned to either of the two
44 treatment groups.

45 Standard exercise education includes exercises
46 currently prescribed by physical therapists, like
47 stretching and strengthening activities. Load
48 modification education also includes exercises
49 currently prescribed by physical therapists, like
50 stretching and strengthening activities, but will
51 also include education on common daily
52 postures and movement patterns that may
53 increase load and stress on the muscles and
54 tendons around your hip.

You will know which exercise group you have been assigned, but the individual testing you will not and cannot know to which group you have been assigned. Each time you see the individual testing you, he/she will remind you they cannot know to which group you have been assigned and to avoid discussing any details of your exercise program with that person. If the individual testing you learns to which group you have been assigned, it could influence or invalidate the results of the study.

66 Participants in BOTH groups will:
67

- 68 • *complete questionnaires related to current pain level and level of function.*

69 You will be asked to complete these questionnaires at baseline, and 4 weeks, 3 months,
70 and 6 months after your initial study visit. During your 4-week home program, you will
71 also be asked to complete weekly questionnaires about compliance with and response to
72 your home program and your activity level.

73 • *consult with an on-sight physical therapist with an expertise in hip rehabilitation.* The
74 physical therapist will provide verbal and written education regarding the assigned
75 treatment.

77 You will complete all of your questionnaires online. On the days of your visit with the physician,
78 you can complete your questionnaires in the office on the computer desktop or tablet made
79 available to you. For the questionnaires we ask you to complete weekly during your 4-week
80 home program, a unique link will be sent to your email address or a study personnel will contact
81 you verbally via telephone each week. This will allow you to access your weekly survey at your
82 convenience from your home computer, smartphone or telephone.

83
84 **In order to assess the effectiveness of the physical therapy treatments, you cannot receive
85 other treatment (ie. corticosteroid injections, surgery, other types of physical therapy)
86 during the 4 week exercise period.** This 4-week 'wait period' is consistent with recommended
87 waiting periods after receiving a corticosteroid injection, another common treatment for GTPS.

88 A 4-week follow-up visit with your physician is standard of care for patients with GTPS at Ohio
89 State Sports Medicine. This allows you, with your physician, to evaluate the effects of common
90 treatments like medication, injections, 'wait and see' advice, and/or physical therapy. Our
91 research will work within this same 4-week 'trial' period during your regularly scheduled
92 doctor's visits to provide one of two different types of exercise education. As with any standard
93 of care doctor's visit, you (and your insurance company) will be billed for the costs. There is no
94 additional cost to participate in the research; your time with the physical therapist during these
95 two sessions is not billed to you or your insurance company.

96 After the 4 week initial study period, you can pursue any other treatment of their choice,
97 including treatment provided to the other group. At the standard of care 4-week follow-up, you
98 can request the exercise program of the other group. There will be no additional cost associated
99 with this education session.

100 Through your 3 month and 6 month questionnaires, we will ask you to provide information about
101 other treatments you have had since enrollment into the study. You will automatically receive a
102 link via email to your questionnaires at 3- and 6- months. We may follow-up with you again by
103 email or by phone if your questionnaires are not completed within one week of the automated
104 message. You are not required, as part of this study, to attend any physician follow-ups.

105
106 **4. How long will I be in the study?**

107
108 Your total time commitment to the study will be approximately 2 hours.

109 You will spend about 3-5 minutes with study personnel reviewing your health history in order to
110 determine your eligibility. If they determine you are not eligible, your time in the study is
111 complete.

112 If you are eligible, you will then spend approximately 30 additional minutes during their baseline
113 visit to complete consent paperwork, online surveys/questionnaires, and the treatment. During
114 their 4-week follow-up, participants will spend about 8-10 minutes completing online
115 questionnaires. Online or telephone questionnaires will be completed weekly over the first 4
116 weeks (8-10 minutes each), and at 3 and 6 months post-baseline (10-15 minutes each). If you

117 choose to complete the home program as instructed (daily), you will spend about 15-20 minutes
118 each day for 4 weeks performing home exercises, regardless of which exercise education
119 program you were assigned.

120 **5. Can I stop being in the study?**

121
122 You may leave the study at any time. If you decide to stop participating in the study, there
123 will be no penalty to you, and you will not lose any benefits to which you are otherwise entitled.
124 Your decision will not affect your future relationship with The Ohio State University.

125
126 **6. What risks, side effects or discomforts can I expect from being in the study?**

127
128 After you enroll in the study, a study team member will review with you your health history
129 in order to confirm your eligibility to participate. This will take approximately 3-5 minutes. If
130 they determine you are not eligible, you will be withdrawn from the study and will not complete
131 any of the testing. At this time, you can ask to receive the exercise handouts provide to
132 participants. You will not be asked to complete any follow-up testing.

133 The tasks associated with this study, including a physical examination and performance of
134 exercises, have typical risks associated with any physical exertion, including post-activity
135 soreness or in rare cases, muscle strains. All activities in this study are considered standard of
136 care and have no greater risks associated with them than typical exercise or physical therapy
137 evaluation and treatment.

138
139 **7. What benefits can I expect from being in the study?**

140 You may experience pain relief and/or improved function as a result of study participation.
141 Your participation may also improve our understanding of the most effective treatment of
142 individuals with GTPS.

143
144 **8. What other choices do I have if I do not take part in the study?**

145
146 You may choose not to participate without penalty or loss of benefits to which you are
147 otherwise entitled.

148
149 **9. What are the costs of taking part in this study?**

150
151 There are no direct costs associated with taking part in this study; however, your insurance
152 will be billed as it typically would for medical care for physician and physical therapy
153 appointments.

154
155 **10. Will I be paid for taking part in this study?**

156
157 You are eligible to receive \$60 in gift cards over the course of the study. You will receive a
158 gift card after completion of the questionnaires, both at the initial visit after the intervention
159 (\$20) and the 4-week follow-up visit (\$20). You will receive an additional \$20 gift card if you

160 complete all of the weekly online/telephone surveys between the initial and follow-up visits. You
161 will not receive compensation for the 3- month and 6- month questionnaires. By law, payments
162 to subjects are considered taxable income.

163

164 **11. What happens if I am injured because I took part in this study?**

165

166 If you suffer an injury from participating in this study, you should notify the principal
167 investigator of this study as soon as possible. The principal investigator will determine if you
168 should obtain a medical evaluation.

169

170 The cost for this treatment will be billed to you or your medical or hospital insurance. The
171 Ohio State University has no funds set aside for the payment of health care expenses for this
172 study.

173

174 **12. What are my rights if I take part in this study?**

175

176 If you choose to participate in the study, you may discontinue participation at any time
177 without penalty or loss of benefits. By signing this form, you do not give up any personal legal
178 rights you may have as a participant in this study.

179

180 You will be provided with any new information that develops during the course of the
181 research that may affect your decision whether or not to continue participation in the study.

182

183 You may refuse to participate in this study without penalty or loss of benefits to which you
184 are otherwise entitled.

185 An Institutional Review Board responsible for human subjects research at The Ohio State
186 University reviewed this research project and found it to be acceptable, according to applicable
187 state and federal regulations and University policies designed to protect the rights and welfare of
188 participants in research.

189

190 **13. Will my study-related information be kept confidential?**

191

192 All information related to your study eligibility will be retained in a locked file drawer,
193 accessible only to approved study personnel. If you are eligible to complete the surveys, we will
194 work to make sure that no one sees your survey responses without approval. But, because we are
195 using the Internet to collect your surveys, there is a chance that someone could access your
196 online responses without permission. In some cases, this information could be used to identify
197 you. Your data will be protected with a code to reduce the risk that other people can view the
198 responses.

199 Efforts will be made to keep your study-related information confidential. However, there
200 may be circumstances where this information must be released. For example, personal
201 information regarding your participation in this study may be disclosed if required by state law.

202

203 Also, your records may be reviewed by the following groups (as applicable to the research):

- 204 • Office for Human Research Protections or other federal, state, or international
205 regulatory agencies;
- 206 • U.S. Food and Drug Administration;
- 207 • The Ohio State University Institutional Review Board or Office of Responsible
208 Research Practices;
- 209 • The sponsor supporting the study, their agents or study monitors; and
- 210 • Your insurance company (if charges are billed to insurance).

211
212 A description of this clinical trial will be available on <http://www.ClinicalTrials.gov>, as
213 required by U.S. law. This website will not include information that can identify you. At most,
214 the website will include a summary of the results. You can search the website at any time.

215
216 **14. HIPAA AUTHORIZATION TO USE AND DISCLOSE INFORMATION FOR**
217 **RESEARCH PURPOSES**

218
219 **I. What information may be used and given to others?**

- 221 • Past and present medical records;
- 222 • Research records;
- 223 • Records about phone calls made as part of this research;
- 224 • Records about your study visits;
- 225 • Information that includes personal identifiers, such as your name, or a number
226 associated with you as an individual;
- 227
- 228 • Information gathered for this research about:
 - 229 Physical exams
 - 230 Diagnostic imaging
 - 231 Diaries and questionnaires
- 232 • Records about any intervention you received including, but not limited to:
 - 233 Corticosteroid injection
 - 234 Prescription pain medication
 - 235 Physical Therapy
 - 236 Surgery

237
238 **II. Who may use and give out information about you?**

239
240 Researchers and study staff may use information about you. The information you provide as
241 part of this study is accessible only to trained research staff with approved access to your
242 data. Only deidentified data (ie. data that cannot be traced back to you) would be given out.
243 Primarily, this is done in the form of research or educational presentations or publications.

244
245 **III. Who might get this information?**

247 • Authorized Ohio State University staff not involved in the study may be aware that
248 you are participating in a research study and have access to your information;
249 • If this study is related to your medical care, your study-related information may be
250 placed in your permanent hospital, clinic or physician's office record;
251

252 **IV. Your information may be given to:**

253 • The U.S. Food and Drug Administration (FDA), Department of Health and Human
254 Services (DHHS) agencies, and other federal and state entities;
255 • Governmental agencies in other countries;
256 • Governmental agencies to whom certain diseases (reportable diseases) must be
257 reported; and
258 • The Ohio State University units involved in managing and approving the research
259 study including the Office of Research and the Office of Responsible Research
260 Practices.
261

262 **V. Why will this information be used and/or given to others?**

263 • To do the research;
264 • To study the results; and
265 • To make sure that the research was done right.
266

267 **VI. When will my permission end?**

268 This permission will be good until 3 years after the last participant completes their 6 month
269 survey/questionnaires.

270 **VII. May I withdraw or revoke (cancel) my permission?**

271 Yes. Your authorization will be good for the time period indicated above unless you change
272 your mind and revoke it in writing. You may withdraw or take away your permission to use and
273 disclose your health information at any time. You do this by sending written notice to the
274 researchers. If you withdraw your permission, you will not be able to stay in this study. When
275 you withdraw your permission, no new health information identifying you will be gathered after
276 that date. Information that has already been gathered may still be used and given to others.
277

278 **VIII. What if I decide not to give permission to use and give out my health
279 information?**

280 Then you will not be able to be in this research study and receive research-related treatment.
281 However, if you are being treated as a patient here, you will still be able to receive care.
282

283 **IX. Is my health information protected after it has been given to others?**

291 There is a risk that your information will be given to others without your permission. Any
292 information that is shared may no longer be protected by federal privacy rules.

293
294 **X. May I review or copy my information?**

295
296 Signing this authorization also means that you may not be able to see or copy your study-
297 related information until the study is completed.

298
299 **15. Who can answer my questions about the study?**

300 For questions, concerns, or complaints about the study, or if you feel you have been harmed as a
302 result of study participation, you may contact
303 **Stephanie Di Stasi: phone (614) 685-9779; email: stephanie.distasi@osumc.edu**
304 **Kate Martin: phone: (614) 293-2385; email: kathryn.martin4@osumc.edu**

305
306 For questions related to your privacy rights under HIPAA or related to this research
307 authorization, please contact the **HIPAA Privacy Officer: Address: Suite E2140, 600**
308 **Ackerman Road, Columbus, OH 43210; Phone: (614) 293-4477**

309
310 For questions about your rights as a participant in this study or to discuss other study-related
311 concerns or complaints with someone who is not part of the research team, you may contact Ms.
312 Sandra Meadows in the Office of Responsible Research Practices at 1-800-678-6251.

313
314 If you are injured as a result of participating in this study or for questions about a study-
315 related injury, you may contact:

316 **Stephanie Di Stasi: phone (614) 685-9779; email: stephanie.distasi@osumc.edu**
317

318 **Signing the consent form**

319
320 I have read (or someone has read to me) this form and I am aware that I am being asked to
321 participate in a research study. I have had the opportunity to ask questions and have had them
322 answered to my satisfaction. I voluntarily agree to participate in this study.

323
324 I am not giving up any legal rights by signing this form. I will be given a copy of this
325 combined consent and HIPAA research authorization form.

326

Printed name of subject	Signature of subject	
		AM/PM
	Date and time	
Printed name of person authorized to consent for subject (when applicable)	Signature of person authorized to consent for subject (when applicable)	
		AM/PM
Relationship to the subject	Date and time	

327

328

329

330 **Investigator/Research Staff**

331

332 I have explained the research to the participant or his/her representative before requesting the
333 signature(s) above. There are no blanks in this document. A copy of this form has been given
334 to the participant or his/her representative.

335

Printed name of person obtaining consent	Signature of person obtaining consent	
		AM/PM
	Date and time	

336

337

338

Witness(es) - May be left blank if not required by the IRB

Printed name of witness	Signature of witness	
		AM/PM
	Date and time	

339

Printed name of witness	Signature of witness	
		AM/PM
	Date and time	